The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a 90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a 25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.

Antibodies recognizing TAG-72 provide a novel approach for the imaging, detection, and treatment of cancer. These methods are made possible by using antibody fragments that bind specifically to the sialyl-Tn surface adhesin of TAG-72. Antibody fragment derivatives are advantageously useful over other antibody and antibody fragments known in the art because they are easy to express in large quantities, can penetrate tissues easily and lack the constant domains that promote often unwanted and usually superfluous effector functions.

The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ?90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ?25 kDa syndecan-1 fragment is detectable in dry, but no normal tears.

Provided is a method for measuring a glycoprotein using an enzymatic method, and the method includes simplified steps.

Provided is a reagent that is suitable for measurement of a glycoprotein and contains a compound capable of stabilizing a leuco dye.

In an aspect, there is provided a method for differentiating movement disorders in a subject, comprising performing a seeding amplification assay for alpha-synuclein in a subject sample utilizing a specific buffer conditions, measuring the alpha-synuclein aggregation of the sample in the assay based on at least one of the following kinetic parameters: lag time, growth phase, T50, ThT max and AUC; and differentiating between Parkinson's Disease (PD) and Multiple System Atrophy (MSA) based on said sample kinetic parameters compared to control kinetic parameters, wherein control kinetic parameters for MSA show at least a two-fold difference from the control kinetic parameters for PD.

The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ?90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ?25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.

Provided are methods of diagnosis and differentiation of and between PD and DLB tissue samples.

The present invention relates to the characterization and production of adalimumab.

In the present invention a method is provided for capillary electrophoresis-based (CE-based) comprehensive N-glycan analysis of urinary PSA. The method is useful for analysis of PSA glycans from urine and for diagnosis of PSA-related conditions.